BioLineRx (BLRX) Other Non-Current Liabilities (2011 - 2025)

BioLineRx's Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $3.7 million for Q4 2025.

• On a quarterly basis, Other Non-Current Liabilities fell 31.32% year-over-year to $3.7 million in Q4 2025; TTM through Dec 2025 was $3.7 million, a 31.32% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, down 31.32% from the prior year.
• Other Non-Current Liabilities steadied at $3.7 million in Q4 2025 per BLRX's latest filing, from $3.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $15.4 million in Q2 2023 and bottomed at $975000.0 in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $4.7 million (2021), against an average of $5.9 million.
• Biggest YoY gain for Other Non-Current Liabilities was 2782.97% in 2021; the steepest drop was 81.81% in 2021.
• Year by year, Other Non-Current Liabilities stood at $1.9 million in 2021, then surged by 142.55% to $4.5 million in 2022, then surged by 164.63% to $11.9 million in 2023, then tumbled by 55.02% to $5.4 million in 2024, then slumped by 31.32% to $3.7 million in 2025.
• Per Business Quant, the three latest BLRX Other Non-Current Liabilities figures stand at $3.7 million (Q4 2025), $3.7 million (Q3 2025), and $4.4 million (Q2 2025).